Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VANGUARD: Atezolizumab plus Bevacizumab after Carbon Ion Radiotherapy in Hepatocellular Carcinoma
jRCT2031240284Phase 2Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicities (DLTs) proportion (Phase Ib) and 1-year recurrence-free survival rate (Phase II). Started Aug 2024; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2031240284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240284.